Sanofi/Novo Nordisk In Head-To-Head Diabetes Combo Approvals
Sanofi and Novo Nordisk – which are battling to shore up their diabetes franchises in the face of biosimilar competition – have simultaneously garnered US approval for new combination products to treat the disease. However, analysts expect the two companies to adopt different pricing strategies.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.